Zomedica Pharmaceuticals ( (ZOM) ) has issued an update.
Zomedica Corp. announced the delisting of its common shares from the NYSE American exchange due to low selling prices, with plans to transition to the OTCQB Venture Market under the ticker symbol ‘ZOMDF’. Despite the delisting, Zomedica remains committed to engaging with investors and advancing its veterinary product pipeline, ensuring continued innovation and value delivery in the animal health sector.
More about Zomedica Pharmaceuticals
Zomedica Corp. is a leading veterinary health company focused on improving animal health by providing innovative therapeutic and diagnostic solutions for equine and companion animals. Their products include the PulseVet shock wave system, Assisi Loop therapeutic devices, TRUFORMA diagnostic platform, TRUVIEW digital cytology system, and VetGuardian no-touch monitoring system.
YTD Price Performance: -30.71%
Average Trading Volume: 5,468,710
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $95.35M
For detailed information about ZOM stock, go to TipRanks’ Stock Analysis page.